Sanofi-Aventis

Chris Viehbacher, born March 26, 1960, holds German and Canadian nationalities. He is a graduate of the Queens University (Ontario - Canada) and a certified public accountant. After beginning his career at PriceWaterhouseCoopers, between 1988-2008 he acquired broad international experience in Europe, in the United States and in Canada with the GlaxoSmithKline (GSK) company. In his last position, Chris Viehbacher was President, Pharmaceutical Operations North America, a member of the board and Co-Chairman of the Portfolio Management Board. As from December 1, 2008, Chris Viehbacher is a sanofi-aventis board member, CEO and a member of the Strategy Committee. Chris Viehbacher is a Board member of PhRMA in the United States. Chris Viehbacher is married with three children. He speaks French, English and German: he lived in France for nine years and was made a knight of the French Legion of Honor in 2003.

Jean-Pierre Lehner holds a Medical degree from the School of Medicine University of Paris, France. After spending four years as Chef de Clinique, assistant of Paris Hospitals, Department of Cardiology (Pr Tricot), Hôpital Bichat, Paris, France, Jean-Pierre Lehner joined Roussel Laboratories in 1981 as Medical Director (1981-1986) and was then named Medical Director of Roussel-Uclaf (1986-1992). He was successively Senior Director of Clinical Investigations of Sanofi Recherche (1992-1996), Scientific Senior Director of Sanofi Winthrop (1996-2002), Vice President Medical Affairs Europe of sanofi-aventis (2003-2005) and Senior Vice-President, Medical & Regulatory Affairs of sanofi-aventis since 2005. He was appointed to his present position in February 2009.

Jérôme Contamine is a Graduate of Ecole Polytechnique (X), France’s most prestigious engineering school, and ENSAE, the national statistics and economics engineering school, affiliated with the Ministry of Finance. He graduated from the elite ENA - Ecole Nationale d’Administration - opting for the French Court of Audit - “Cour des Comptes” in 1984. After 4 years at the “Cour des Comptes”, as a Senior State General Auditor, he joined Elf Aquitaine in 1988, as advisor to the Chief Financial Officer, and became Group Finance Director & Treasurer in 1991. He became the General Manager of Elf Petroleum Norway in 1995, after being named Deputy Vice President of Elf Upstream Division for Europe and the U.S. In 1999, he was appointed Head of the taskforce for integration with Total, in charge of the reorganization of the merged entity, TotalFinaElf, and became, in 2000, Vice President Europe and Central Asia, Upstream Division of Total. The same year, he joined Vivendi Environnement as CFO, Deputy General Manager and member of the Board. In 2003, he became Senior Executive Vice President, Deputy General Manager and Chief Financial Officer of Veolia Environment. He was appointed to his current position in March 2009.

Laurence Debroux is a graduate of HEC (Ecole des Hautes Etudes Commerciales). She began her career with Merrill Lynch in London, and then worked in the Finance Department of the Elf Aquitaine Group from 1993 to 1996. She joined the Sanofi Group as Corporate Treasurer in 1996, and was appointed Head of Financing/Treasury in 1997. From 2000 to 2004, she served as Head of Strategic Planning, before becoming Deputy Chief Financial Officer. As from March 2007 she was appointed Senior Vice President, Chief Financial Officer and became a member of the Executive Committee in December 2008. She was appointed to her current position in February 2009.

Hanspeter Spek graduated from business school in Germany. In 1974, he completed a management training program at Pfizer International, and then joined Pfizer RFA as a junior product manager. He served in various positions at Pfizer RFA, including as manager of the marketing division. Mr. Spek joined Sanofi Pharma GmbH, a German subsidiary of Sanofi, in 1985 as Marketing Director, and served in various positions in Germany and then at Sanofi in France, before being named Senior Vice President Europe following the merger with Synthélabo in 1999. He served as Executive Vice President, International Operations from October 2000, until January 2003, when he was named in charge of worldwide operations of Sanofi-Synthélabo. He was appointed to his present position in August 2004.

Antoine Ortoli is a graduate of the Ecole Supérieure de Commerce in Rouen, France, and of INSEAD. He also holds a law degree and an accountancy qualification. He began his career in 1980 as a financial and systems auditor with Arthur Young and Co. In December 1981, he joined the Sanofi Group, where he served in a variety of positions, including Finance Director of the Pharmaceuticals Division and Director of the Latin America region. Following the merger with Synthélabo in 1999, he was named as Vice President, Latin America, and then as Senior Vice President, Asia Middle East in June 2001. In June 2003, he took on the role of Vice President, Intercontinental region at Sanofi-Synthélabo. He was appointed to his present position in January 2005.

Christian Lajoux has a degree (DEUG) in psychology, a bachelor degree (maîtrise) in philosophy and a post-graduate degree (DESS) in personnel management from the Institut d’Administration des Entreprises (IAE Paris). He served in a variety of positions at Sandoz, including Division Director, before joining Sanofi Winthrop in 1993. He then served in various positions, including Director of Operations and Managing Director of Sanofi Winthrop France, before being appointed Senior Vice President France just prior to the merger with Synthélabo in 1999. He served in that position until being named as Senior Vice President Europe in January 2003, and then as Senior Vice President Pharmaceutical Operations France in August 2004. He was appointed as Chairman of Leem (Les entreprises du médicament) in July 2006 and Chairman of FEFIS (Fédération Française des Industries de Santé) in December 2008. 112

Gilles Lhernould has a diploma in pharmacy and a master’s degree (DEA) in industrial pharmacy. He began his career as a manufacturing supervisor at Laboratoires Bruneau, and in 1983 joined one of Sanofi’s subsidiaries where he managed production and later the factory. Mr. Lhernould then served in a variety of positions within the Sanofi Group, including Director of Human Resources — Pharmaceuticals for Sanofi Pharma and Director of Operational Human Resources for Sanofi. Following the merger with Synthélabo in 1999, he served as Vice President in charge of integration and then Vice President of Information Systems, before being named as Senior Vice President, Industrial Affairs and Senior Vice President Industrial Affairs of sanofi-aventis. He was appointed to his present position effective September 2008.

Marie-Hélène Laimay has a degree in business from a French business school (Ecole Supérieure de Commerce et d’Administration des Entreprises) and a DECS (an accounting qualification). She spent three years as an auditor with Ernst & Young before joining Sanofi in 1985. Mrs. Laimay served in a variety of financial positions, including Financial Director of Sanofi’s beauty division and Deputy Financial Director of Sanofi- Synthélabo following the merger with Synthélabo in 1999. From November 2000 to May 2002, she served as Vice President, Internal Audit, and from May 2002 to August 2004 as Senior Vice President, Chief Financial Officer, before being appointed to her present position.

Olivier Charmeil is a graduate of HEC (Ecole des Hautes Etudes Commerciales) and of the Institut d’Etudes Politiques in Paris. From 1989 to 1994, he worked in the Mergers & Acquisitions department of Banque de l’Union européenne. He joined Sanofi Pharma in 1994 as head of Business Development. Subsequently, he held various posts within the Group, including Chief Financial Officer (Asia) for Sanofi-Synthélabo in 1999 and Attaché to the Chairman, Jean-François Dehecq, in 2000, before being appointed as Vice President, Development within the Sanofi-Synthélabo International Operations Directorate, where he was responsible for China and support functions. In 2003, Olivier Charmeil was appointed Chairman and Chief Executive Officer of Sanofi- Synthélabo France, before taking the post of Senior Vice President, Business Management and Support within the Pharmaceutical Operations Directorate. In this role, he piloted the operational integration of Sanofi- Synthélabo and Aventis. He was appointed to his current position in February 2006. Since January 1, 2008, Operations Japan have reported to Olivier Charmeil.

Philippe Fauchet is a graduate of HEC (Ecole des Hautes Etudes Commerciales), and also holds a law degree. After two years with a subsidiary of Renault, Philippe Fauchet joined Roussel Uclaf in 1984, and, held a number of posts in France, Japan and Korea, before becoming Vice President of the Asia-Pacific region for Hoechst Marion Roussel. He joined Sanofi in 1996, and headed up the Eastern Europe region from 1997, before becoming Vice President, Eastern Europe for Sanofi-Synthélabo in 1999. Philippe Fauchet took over as head of Sanofi-Synthélabo’s Japanese operations in June 2001 and was appointed as Senior Vice President Pharmaceutical Operations, Japan in May 2005. He is also an advisor to the French Foreign Trade Commission. He was appointed to his current position in January 2009.

Philippe Peyre is a graduate of the Ecole Polytechnique, and began his career in management consultancy with Bossard before being appointed as a member of the General Management Committee of Bossard Gemini Consulting. In 1998, he joined Rhône-Poulenc Rorer as Senior Vice President Special Projects, and then served as Head of Integration at Aventis Pharma, and as Company Secretary and Senior Vice President, Business Transformation of Aventis. He was appointed to his present position in August 2004.

Pierre Chancel, a pharmacist, is a graduate of the Institut de Pharmacie Industrielle in Paris. At Rhône- Poulenc, from 1994 to 1996, he was Marketing Director for Théraplix. From 1997 to 1999, Mr. Chancel served as Business Unit Manager in charge of products in the central nervous system, rheumatology and hormone replacement therapy fields. From 2003, he served as Managing Director of Aventis Operations in the United Kingdom and Ireland. Before being appointed to this position, he was in charge of global strategy development at Aventis, which led to the launch of the new diabetes treatment Lantus®. He was appointed to his present position in August 2004.

Gregory Irace holds a B.S. in accounting from Albany State University (New York). He began his career at Price Waterhouse in 1980 and received his CPA in 1982. He spent 11 years at Price Waterhouse becoming a Senior Audit Manager in 1988, and a Senior Manager in the Corporate Finance Department in 1989. In 1991 he joined Sterling Winthrop Inc. as Regional Controller and in 1993 he became Director of Financial Planning and Analysis for Sanofi Winthrop L.P. From October 1994 to January 2007, he was Chief Financial Officer of Sanofi’s Pharmaceutical Operations in the United States, most recently serving as Senior Vice President, Finance and Administration and Chief Financial Officer of sanofi-aventis US. He was appointed to his present position in February 2007.

Jean-Philippe Santoni holds a doctorate in Medicine and a masters’ degree in Human Biology. He began his career as a clinician specializing in hospital medicine and biology at various Academic Hospitals from the “Assistance Publique – Hôpitaux de Paris” (APHP group). From 1985, he held various posts with responsibility for international clinical development and medical/regulatory affairs, first with Servier and subsequently with American Cyanamid/Lederlé. In 1990, he joined Synthélabo as International Medical Director. Following the merger with Sanofi in 1999, he served successively as Associate Vice President Medical and Regulatory Affairs, Vice President International Clinical Operations and Vice President International Clinical Development, a position he retained after the merger with Aventis in 2004. He was appointed to his present position in January 2007.

Karen Linehan graduated from Georgetown University with bachelor of arts and juris doctorate degrees. Prior to practicing law, Ms. Linehan served on the congressional staff of the Speaker of the U.S. House of Representatives from September 1977 to August 1986. Until December 1995, she was an Associate in a law firm in New York, New York. In January 1996, she joined Sanofi as Assistant General Counsel of its US subsidiary. In July 1996, Ms. Linehan moved to Paris to work on international matters within the Group and she has held a number of positions within the Legal Department, most recently as Vice President - Deputy Head of Legal Operations. She was appointed to her current position in March 2007.

Marc Cluzel is a Doctor of Medicine and a Doctor of Science. He began his career in hospital medicine before carrying out research at Johns Hopkins University (Baltimore) and Guy’s Hospital (London). In 1991, he joined Sanofi Recherche as a clinical pharmacologist, and was then appointed successively as Senior Project Director in 1993, Vice President, Research Projects Management in 1996 (retaining this position after the 1999 merger with Synthélabo) and Vice President, International Development in 2001 (retaining this position after the 2004 merger with Aventis). Marc Cluzel was appointed to his current position in January 2007.

Michel Labie is a graduate of the Taipei Ecole Normale de Langues (Taiwan), holds a diploma in Chinese from the Institut National des Langues et Civilisations Orientales (INALCO) and a bachelor degree (maîtrise) in Chinese Traditional Pharmacopoeia. He began his career with Sanofi in 1981, opening the company’s Beijing bureau in China in 1982. In 1995, he moved to France as Head of International Professional Relations, before becoming Head of Institutional and Professional Relations in 2001. Michel Labie was appointed Vice President, Assistant Director of Communication in June 2006, and took up his current post in November 2006, retaining his responsibilities in the Institutional and Professional Relations Department.

Philippe Luscan has graduated from Ecole Polytechnique and Ecole des Mines of Paris in biotechnologies. He started his career in 1987 as Head of production at Danone. In 1990, he joined the Group as Head of site at Sanofi Chemistry in Sisteron and was then named Head of industrial affairs at Sanofi in the United States followed by an appointment as Vice President Supply Chain, before being named Vice President Chemistry in September 2006. He was appointed to his present position in September 2008.

Wayne Pisano holds a bachelor’s degree in biology from St. John Fisher College, Rochester, New York, and an MBA from the University of Dayton, Ohio. Prior to sanofi pasteur he held various marketing and sales positions with Reed and Carnrick Pharmaceuticals and Sandoz/Novartis. He joined sanofi pasteur as Vice President, U.S. Marketing in May 1997 and then served as Senior Vice President of US Marketing & Sales, Executive Vice President of sanofi pasteur North America and Senior Vice President, Global Commercial Operations. He was appointed to his present position in August 2007.

Chairman of Policy Committee of the French Strategic Investment Found • Director of Air France, Agence Nationale de la Recherche and Veolia Environnement • Member of IFPMA (International Federation of Pharmaceutical Manufacturers Associations) • Chairman of Association Nationale de la Recherche Technique • Chairman of the Board of Directors of ENSAM (Ecole Nationale Supérieure d’Arts et Métiers) • Member of Fondation Française pour la Recherche sur l’Epilepsie

• Vice President, General Manager Administration and Finance of L’Oréal • Chairman of the Board of Directors of Regefi • Director of DG 17 Invest, L’Oréal USA Inc. and The Body Shop International (United Kingdom)

Mrs. Claudie Haigneré is a certified rheumatologist and holds a doctorate in science specialized in neurosciences. She participated in several spatial missions (Station MIR in 1996, International Space Station in 2001). She also served as Ministre Français Délégué à la Recherche et aux Nouvelles Technologies (2002-2004) and as Ministre Français Délégué aux Affaires Européennes (2004-2005). Since November 2005, Mrs. Claudie Haigneré has been an Advisor of the Director General of the European Space Agency (ESA).

• Director of Groupe Eurotunnel, Europacorp and Eurotunnel NRS Holders Company Limited (United Kingdom) • Member of the Audit Committee of Europacorp

Mr. Gunter Thielen has a doctorate in physical chemistry and a degree in economics and industrial engineering. Since January 2008, he has served as Chairman of the Supervisory Board of Bertelsmann AG, Gütersloh and Chairman of the Executive Board of Bertelsmann Stiftung (Foundation Bertelsmann).

Chairman of the Supervisory Boards of Vivendi and Groupe Canal + • Member of the Supervisory Boards of Axa and Maroc Telecom • Director of Cap Gemini SA, Axa Millésimes SAS, Nestlé (Switzerland) and NBC Universal Inc. (United States),

• Director of Labelux Group GmbH (Austria) • Director and Chairman of the Audit Committee of Coty Inc., New York • Member of the Supervisory Board and Chairman of the Audit Committee of DWS Investment GmbH, Frankfurt (Germany)

• Chairman of the Board of Directors of L’Oréal • Chairman of the Strategy Committee of L’Oréal • Chairman of the Board of Directors of Fondation d’Entreprise L’Oréal (Foundation) • Chairman of Alba Plus, L’Oréal UK Ltd and L’Oréal USA Inc. • Vice Chairman of the Board of Directors of L’Air Liquide • Director of Ferrari S.p.A. (Italia)

Mr. Patrick de la Chevardière is a graduate of the Ecole Centrale de Paris. Since September 2003, he has served as Deputy Chief Financial Officer of Total.

Chairman of the Board of Directors and Chairman of the Appointment and Governance Committee of Total S.A. • Chairman of Fondation Total (Foundation) • Director and member of the Appointments Committee and the Compensation Committee of L’Air Liquide • Director and member of the Compensation Committee of Renault SA • Director of Renault SAS, Bombardier Inc. (Toronto — Canada) since January 21, 2009 and Musée du Louvre • Member of the Supervisory Board of Areva • Member of the Board of Directors of AFEP and Ecole Polytechnique • Chairman of Fondation de l’Ecole Polytechnique (Foundation)

Mr. Uwe Bicker is a physician and holds a doctorate in chemistry. He is a Professor at the Medical Faculty of the Heidelberg University and a Doctor honoris causa at the Klausenburg University. He has been a member of the Board of Bertelsmann Stiftung (Foundation Bertelsmann) since January 2008.